恩扎卢胺联合[177Lu]Lu-PSMA-617对比恩扎卢胺单药治疗转移性去势抵抗性前列腺癌的总生存与生活质量(ENZA-p):多中心、开放标签、随机2期试验的次要结局
ENZA-p试验在澳大利亚15家医院纳入未接受过多西他赛或雄激素受体通路抑制剂治疗的转移性去势抵抗性前列腺癌患者,随机接受恩扎卢胺单药或联合自适应剂量[177Lu]Lu-PSMA-617。中位随访34个月,联合组总生存优于单药组(中位34 vs 26个月,HR 0.55),身体功能和总体健康/生活质量恶化无生存期也占优,但联合组自评口干频率更高。
要点
- 联合组中位总生存34个月 vs 单药组26个月,HR 0.55(95%CI 0.36-0.84),log-rank p=0.0053。
- 联合组身体功能恶化无生存期10.64个月 vs 单药组3.42个月,HR 0.51(95%CI 0.36-0.72)。
- 联合组总体健康与生活质量恶化无生存期8.71个月 vs 单药组3.32个月,HR 0.47(95%CI 0.33-0.67)。
核心结论
- 在恩扎卢胺基础上加用[177Lu]Lu-PSMA-617与高危转移性去势抵抗性前列腺癌患者总生存改善及部分健康相关生活质量维度改善相关。
- 作者认为该发现值得在转移性前列腺癌患者中开展自适应剂量[177Lu]Lu-PSMA-617联合雄激素受体通路抑制剂的3期评估。
研究设计与样本
- ENZA-p为多中心、开放标签、随机2期试验,在澳大利亚15家医院开展。
- 纳入18岁及以上、未接受过多西他赛或雄激素受体通路抑制剂治疗的转移性去势抵抗性前列腺癌男性,镓-68[68Ga]Ga PSMA-PET-CT阳性,ECOG体能状态0-2,且至少有两个恩扎卢胺早期进展危险因素。
- 采用中央网络系统按1:1随机,使用最小化法加随机成分,按研究中心、疾病负荷、早期多西他赛和既往阿比特龙治疗分层。
- 治疗为口服恩扎卢胺160 mg每日一次单药,或联合自适应剂量(两剂或四剂)静脉[177Lu]Lu-PSMA-617 7.5 GBq,每6-8周一次。
- 2020年8月17日至2022年7月26日,79例随机至恩扎卢胺组,83例随机至恩扎卢胺联合[177Lu]Lu-PSMA-617组;中位随访34个月(IQR 29-39)。
主要发现
- 共报告96例死亡:恩扎卢胺组53例(67%),联合组43例(52%)。
- 联合组总生存长于单药组:中位34个月(95%CI 30-37)vs 26个月(95%CI 23-31),HR 0.55(95%CI 0.36-0.84),log-rank p=0.0053。
- 162例参与者中154例(95%)完成健康相关生活质量评估。
- 12个月时身体功能恶化无生存期:联合组中位10.64个月(95%CI 7.66-12.42)vs 单药组3.42个月(95%CI 3.19-7.89),HR 0.51(95%CI 0.36-0.72),log-rank p<0.0001。
- 12个月时总体健康与生活质量恶化无生存期:联合组中位8.71个月(95%CI 6.41-11.56)vs 单药组3.32个月(95%CI 3.09-5.26),HR 0.47(95%CI 0.33-0.67),log-rank p=0.0001。
关键数值与推荐
- 疼痛至进展的平均评分 favoring 联合组优于单药组(差值7.3,95%CI 1.6-12.9;p=0.012)。
- 疲乏至进展的平均评分 favoring 联合组优于单药组(差值5.9,95%CI 1.1-10.7;p=0.016)。
- 自评口干频率单药组低于联合组:43/75(57%)vs 58/78(74%),p=0.039;其他所有领域两组评分无显著差异。
- 3-5级不良事件:恩扎卢胺组35/79(44%),联合组37/81(46%);两组均无归因于研究治疗的死亡。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interim analysis of the ENZA-p trial showed improved prostate-specific antigen (PSA) progression-free survival with the addition of lutetium-177 [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 to enzalutamide as first-line treatment of metastatic castration-resistant prostate cancer. Here, we report the secondary endpoints of overall survival and health-related quality of life (HRQOL) with longer follow-up. METHODS: ENZA-p was a multicentre, open-label, randomised, phase 2 trial done at 15 hospitals in Australia. Participants were men aged 18 years or older who had not previously been treated with docetaxel or androgen receptor pathway inhibitors for metastatic castration-resistant prostate cancer, gallium-68 [68Ga]Ga PSMA-PET-CT-positive disease, an Eastern Cooperative Oncology Group performance status of 0-2, and at least two risk factors for early progression on enzalutamide. Participants were randomly assigned (1:1) by a centralised, web-based system using minimisation with a random component to stratify for study site, disease burden, early docetaxel, and previous treatment with abiraterone. Treatment was oral enzalutamide 160 mg daily alone or with adaptive-dosed (two or four doses) intravenous 7·5 GBq [177Lu]Lu-PSMA-617 every 6-8 weeks. The primary endpoint was prostate-specific antigen (PSA) progression-free survival, which has been previously reported. Overall survival, defined as the interval from the date of randomisation to date of death from any cause, or the date last known alive, and HRQOL were key secondary endpoints. HRQOL was assessed with the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and the Patient Disease and Treatment Assessment Form. For HRQOL analyses, deterioration-free survival was measured from randomisation until the earliest occurrence of death, clinical progression, discontinuation of study treatment; or a worsening of 10 points or more from baseline in physical function, or in overall health and QOL. Analyses of these secondary endpoints were prespecified and are by intention to treat. The trial is registered with ClinicalTrials.gov, NCT04419402, and follow-up is complete. FINDINGS: Between Aug 17, 2020, and July 26, 2022, 79 patients were randomly assigned to enzalutamide and 83 to enzalutamide plus [177Lu]Lu-PSMA-617. 96 deaths was reported after a median follow-up of 34 months (IQR 29-39): 53 (67%) in the enzalutamide group and 43 (52%) in the enzalutamide plus [177Lu]Lu-PSMA-617 group. Overall survival was longer in the enzalutamide plus [177Lu]Lu-PSMA-617 group than the enzalutamide group (median 34 months [95% CI 30-37] vs 26 months [23-31]; HR 0·55 [95% CI 0·36-0·84], log-rank p=0·0053). HRQOL was rated by 154 (95%) of 162 participants. Deterioration-free survival at 12 months and stratified log-rank p values favoured enzalutamide plus [177Lu]Lu-PSMA-617 for both physical function (median 10·64 months [95% CI 7·66-12·42] vs 3·42 months [3·19-7·89]; HR 0·51 [95% CI 0·36-0·72], log-rank p<0·0001) and overall health and QOL (8·71 months [6·41-11·56] vs 3·32 months [3·09-5·26]; HR 0·47 [95% CI 0·33-0·67], log-rank p=0·0001). Mean scores for pain until progression favoured enzalutamide plus [177Lu]Lu-PSMA-617 over enzalutamide (difference 7·3 [95% CI 1·6-12·9]; p=0·012). Mean scores for fatigue until progression favoured enzalutamide plus [177Lu]Lu-PSMA-617 over enzalutamide (difference 5·9 [95% CI 1·1-10·7]; p=0·016). The frequency of self-rated xerostomia was lower in the enzalutamide group than in the enzalutamide plus [177Lu]Lu-PSMA-617 group (43 [57%] of 75 vs 58 [74%] of 78; p=0·039), and scores were not significantly different between groups for all other domains. Grade 3-5 adverse events occurred in 35 (44%) of 79 patients in the enzalutamide group and 37 (46%) of 81 patients in the enzalutamide plus [177Lu]Lu-PSMA-617 group. No deaths were attributed to study treatment in either group. INTERPRETATION: The addition of [177Lu] Lu-PSMA-617 to enzalutamide was associated with improved survival and some aspects of HRQOL in patients with high-risk metastatic castration-resistant prostate cancer. Our findings warrant phase 3 evaluation of adaptive-dosed [177Lu] Lu-PSMA-617 in combination with androgen receptor pathway inhibitors in people with metastatic prostate cancer. FUNDING: The Prostate Cancer Research Alliance initiative (Movember and Australian Federal Government), St Vincent's Clinic Foundation, GenesisCare, RoyMorgan, AdAcAp (a Novartis company), and Astellas.
引用
- Emmett L, Subramaniam S, Crumbaker M, et al. Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025. PMID: 39956124. doi:10.1016/S1470-2045(25)00009-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。